Read More

Synaffix Has Announced The Expansion Of Its License Agreement With Macrogenics Adding Up To Four Antibody-drug Conjugates Programs; Expanded Collaboration Includes Up To $2.2B In Total Potential Payments

The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net

MGNX